Raglan Pharmaceutical & Life Science Projects

Raglan Capital is involved as founder or co-founder in a number of pharmaceutical and life science ventures including Open Orphan plc and Amryt Pharma plc.

Open Orphan

Open Orphan is a rapidly growing niche CRO pharmaceutical services group which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Conducted from Europe’s only 24-bedroom quarantine clinic with onsite virology providing individually isolated rooms and connected to our specialist laboratory facility. Which offers highly specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral, and vaccine discovery and development. Reliable laboratory analysis underpinned by scientific expertise is essential when processing and analysing clinical samples. Robust quality processes support our team of scientists in the delivery of submission ready data.

Open Orphan comprises of two commercial specialist CRO services businesses, hVIVO and Venn Life Sciences, and is developing an early stage orphan drug genomics data platform business. This platform captures valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls), preclinical, Phase I & II clinical trials design and execution. The merger with hVIVO created a European full pharma services group broadening the Group’s customer base and with complementary specialist CRO services, widened the range of the Group’s service offerings.

Open Orphan is a publicly traded company on the London AIM and Euronext Growth stock exchanges under the symbol ORPH. The company was created in-house by Raglan, following the success and learnings of our first life science project, Amryt Pharma plc.

Open Orphan currently has three operating wings that offer a wide range of services.

– hVIVO conducts studies and provides services for customers, both pharmaceutical and biotech companies, utilising a range of different client trial and laboratory methodologies across differing viral challenges.

– Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisation.

– Open Orphan Genomic Health Data is building the first European people-powered health data and genomic data collection platform which will allow us to quickly become one of the leading brokers of rare disease patient data.

Open Orphan can be found on www.openorphan.com

Amryt Pharmaceuticals

Amryt Pharma is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients diagnosed with rare or orphan diseases.

Amryt comprises a growing commercial business and a significant development pipeline. Their aim is to forge partnerships and collaborations that work for all. By interacting with stakeholders, they create a clear path for transformative medicines to reach those that need them.

In 2016, Raglan established Amryt Pharma Plc which is listed on both the London and Euronext exchanged. In 2020 Amryt listed on NASDAQ following the acquisition of Aegerion Pharmaceuticals in September 2019. Amryt is now an established European and North America orphan drug company  and in June 2020 it had a market capitalisation in excess of £281m.

Amryt’s lead drug candidate, AP101, is a potential treatment undergoing phase 3 clinical trials for Epidermolysis Bullosa (“EB”), a rare and distressing genetic skin disorder for which there is currently no treatment.  The European and US market opportunity for EB is estimated to be in excess of €1.3 billion.

Amryt’s earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing’s disease.

In addition, Amryt holds an exclusive licence to sell Lojuxta (lomitapide) across the Europe, the Middle East, Northern Africa, Turkey, Israel and the Commonwealth of Independent States. Lojuxta is an approved treatment for adult patients with the rare cholesterol disorder – Homozygous Familial Hypercholesterolaemia (“HoFH”). This disorder impairs the body’s ability to remove low density lipoprotein cholesterol from the blood.

In March 2018, Amryt in-licensed a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Recessive Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders.

For more information on Amryt, please visit amrytpharma.com